Cargando…
Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer
Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls. Study design: Eighty eight patients (28 with oral cancer, 29...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medicina Oral S.L.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448188/ https://www.ncbi.nlm.nih.gov/pubmed/21743397 http://dx.doi.org/10.4317/medoral.17323 |
_version_ | 1782244228887216128 |
---|---|
author | Brailo, Vlaho Vucicevic-Boras, Vanja Lukac, Josip Biocina-Lukenda, Dolores Zilic-Alajbeg, Iva Milenovic, Aleksandar Balija, Melita |
author_facet | Brailo, Vlaho Vucicevic-Boras, Vanja Lukac, Josip Biocina-Lukenda, Dolores Zilic-Alajbeg, Iva Milenovic, Aleksandar Balija, Melita |
author_sort | Brailo, Vlaho |
collection | PubMed |
description | Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls. Study design: Eighty eight patients (28 with oral cancer, 29 leukoplakia, and 31 healthy controls) were included in this study. Cytokine concentrations were measured by commercial enzyme linked immunoassay. Results: Salivary IL-1β and IL-6 were significantly higher in oral cancer patients than in patients with leukoplakia and control group (p<0.05). No differences in concentrations of salivary TNF-α between either of the groups were observed. Serum concentrations of IL-1β were below level of detection in all but two participants. No significant differences between the groups were observed in serum concentrations of IL-6. Serum TNF-α was significantly higher in control subjects than in oral cancer patients. Conclusions: Patients with oral cancer have elevated levels of inflammatory cytokines in their saliva. Whether this elevation can be used for monitoring the malignant transformation of oral leukoplakia remains to be answered by further follow up studies. Key words: Cytokines, oral, leukoplakia, cancer. |
format | Online Article Text |
id | pubmed-3448188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medicina Oral S.L. |
record_format | MEDLINE/PubMed |
spelling | pubmed-34481882012-10-11 Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer Brailo, Vlaho Vucicevic-Boras, Vanja Lukac, Josip Biocina-Lukenda, Dolores Zilic-Alajbeg, Iva Milenovic, Aleksandar Balija, Melita Med Oral Patol Oral Cir Bucal Research-Article Objectives: The aim of study was to compare salivary and serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral leukoplakia, oral cancer and healthy controls. Study design: Eighty eight patients (28 with oral cancer, 29 leukoplakia, and 31 healthy controls) were included in this study. Cytokine concentrations were measured by commercial enzyme linked immunoassay. Results: Salivary IL-1β and IL-6 were significantly higher in oral cancer patients than in patients with leukoplakia and control group (p<0.05). No differences in concentrations of salivary TNF-α between either of the groups were observed. Serum concentrations of IL-1β were below level of detection in all but two participants. No significant differences between the groups were observed in serum concentrations of IL-6. Serum TNF-α was significantly higher in control subjects than in oral cancer patients. Conclusions: Patients with oral cancer have elevated levels of inflammatory cytokines in their saliva. Whether this elevation can be used for monitoring the malignant transformation of oral leukoplakia remains to be answered by further follow up studies. Key words: Cytokines, oral, leukoplakia, cancer. Medicina Oral S.L. 2012-01 2011-07-15 /pmc/articles/PMC3448188/ /pubmed/21743397 http://dx.doi.org/10.4317/medoral.17323 Text en Copyright: © 2012 Medicina Oral S.L. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research-Article Brailo, Vlaho Vucicevic-Boras, Vanja Lukac, Josip Biocina-Lukenda, Dolores Zilic-Alajbeg, Iva Milenovic, Aleksandar Balija, Melita Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
title | Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
title_full | Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
title_fullStr | Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
title_full_unstemmed | Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
title_short | Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
title_sort | salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer |
topic | Research-Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448188/ https://www.ncbi.nlm.nih.gov/pubmed/21743397 http://dx.doi.org/10.4317/medoral.17323 |
work_keys_str_mv | AT brailovlaho salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer AT vucicevicborasvanja salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer AT lukacjosip salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer AT biocinalukendadolores salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer AT zilicalajbegiva salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer AT milenovicaleksandar salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer AT balijamelita salivaryandseruminterleukin1betainterleukin6andtumornecrosisfactoralphainpatientswithleukoplakiaandoralcancer |